Navigation Links
Myeloma in Medical News

Multiple Myeloma Genome Unlocked

Discovery paves way for better therapies for some blood cancer patients, experts say WEDNESDAY, July 29 (HealthDay News) -- The sequencing of the first three multiple myeloma whole genomes has been completed by U.S. scientists, who said this success will lead to a better understanding ...

CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs

NEW YORK, July 20 /PRNewswire/ -- Cancer Care announced today the launch of the "Door to Door" program for patients with multiple myeloma. Cancer Care 's program will provide individual grants of up to $600 annually to multiple myeloma patients for covering transportation cost...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Multiple Myeloma Therapeutics Market http://www.reportlinker.com/p0119496/World-Multiple-Myeloma-Therapeutics-Market.html?utm_source=PRNWire&utm_medium=PR&utm...

MMRF and the Broad Institute to perform whole genome sequencing of multiple myeloma samples

The Multiple Myeloma Research Foundation (MMRF) announced today a collaboration with the Broad Institute of MIT and Harvard to systematically uncover the molecular changes underlying multiple myeloma by whole genome sequencing of individual patient tumors. The MMRF will provide both patient sample...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

CAMBRIDGE, Mass., Feb. 23 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced that 100 data presentations on VELCADE research will be featured at the Fifth International Myeloma Workshop (IMW) in Washington, D.C., February 26 - March 1, 2009. The 13 oral and 87 poster presenta...

International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease

LOS ANGELES, Feb. 23 /PRNewswire-USNewswire/ -- On Wednesday, February 25, 2009, the Institute for Myeloma and Bone Cancer Research (IMBCR) will host a roundtable discussion bringing leading scientists in the field of cancer research together to discuss monoclonal gammopathy of undetermined signif...

Managing Myeloma (www.managingmyeloma.com) Launches - A Comprehensive Information and Educational Site for Physicians, Nurse Practitioners, Physician Assistants, and Pharmacists

MORRISVILLE, Pa., Feb. 12 /PRNewswire/ -- MediCom Worldwide, Inc., an accredited provider of continuing medical education for physicians, pharmacists, and nurses, announces the launch of an online repository of resources and education on the treatment of multiple myeloma by a multidisciplinary net...

Institute of Myeloma and Bone Cancer Research in Los Angeles Proudly Announces That Ethan Horwitz, Esq of King & Spalding Law Firm has Joined its Board of Directors

LOS ANGELES, Feb. 6 /PRNewswire-USNewswire/ -- Established in 2004, the Institute for Myeloma and Bone Cancer Research (IMBCR) is the only non-profit, independent cancer research institute focused on creating novel therapies and ultimately a cure for multiple myeloma and metastatic bone disease. ...

Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate

NEW BRUNSWICK, N.J., Feb. 3 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US : SNT) today announced results of efficacy, toxicological and dose-finding studies in mice for its potential multiple myeloma drug candidate, SNS-01. SNS-01 is a n...

1.2 Million Dollars Recently Awarded to Institute for Myeloma and Bone Cancer Research

FJC, a foundation of philanthropic donor-advised funds and the Myeloma Research Foundation are the latest major donors to the "Cure Myeloma Project", an ongoing research initiative at the Institute for Myeloma and Bone Cancer Research, (IMBCR), in Los Angeles, CA LOS ANGELES, Jan. 26 /PRNewsw...

Combo Therapy Helps Multiple Myeloma Patients

Three-quarters of those who had relapsed saw disease stabilize or improve, study shows FRIDAY, Dec. 12 (HealthDay News) -- A new combination of medicines designed to boost immune function can help some multiple myeloma patients, according to interim results from an ongoing Mayo Clinic ...

Drug combination improves or stabilizes disease for relapsed multiple myeloma patients

ROCHESTER, Minn. -- Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment. Interim results of an ongoing clinical trial evaluati...

Treatment with anti-anemia drugs may not be safe for multiple myeloma patients

Thessaloniki, Greece - August 4, 2008 - A recent study published in American Journal of Hematology demonstrated that Erythropoiesis-stimulating agents (ESAs), a widely used drug to treat anemia, may have a negative impact on the survival of myeloma patients. In the study, 323 multiple myeloma pa...

How molecules out of balance lead to human multiple myeloma and other cancers

An international team of scientists has identified processes that are heavily implicated in human multiple myeloma and other B cell cancers, moving us closer to developing quick tests and readouts that could help in the tailored treatment of patients. B cells, the white blood cells that produce...

Senesco Expands on Preclinical Multiple Myeloma Findings

NEW BRUNSWICK, N.J., June 5 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today further details of its continuing preclinical multiple myeloma research. In February 2008, the Company announced results of preclinical animal studies in ...

McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute

DETROIT, April 11 /PRNewswire-USNewswire/ -- The McCarty Cancer Foundation has awarded Jeffrey Zonder, M.D., Assistant Professor of Medicine and Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, a $50,000 grant for the multi-center Multiple Myeloma ...

Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients

-- Trial results of combination therapy VELCADE, melphalan and prednisone reported a 32 percent complete remission rate with 85 percent of patients alive at three years -- CAMBRIDGE, Mass., March 13 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLN...

VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today reported the presentation of results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and dexamethasone (VcD) to vincristine, adriamycin and dexamethasone ...

New therapeutic options for newly diagnosed multiple myeloma patients

ATLANTA -- Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomi...

Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

- Data Demonstrate 17.6 Month Overall Survival Advantage in Elderly Myeloma Patients when Thalidomide Is Added to Standard Therapy - Data Presented at the 49th American Society of Hematology Meeting ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today anno...

Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy

- VELCADE based therapy achieved highly significant improvement across all efficacy endpoints including overall survival - ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced the presentation of results from the 682 patient, ran...

Drug Combo Boosts Multiple Myeloma Survival

A thalidomide derivative plus dexamethasone improved outcomes, studies found WEDNESDAY, Nov. 21 (HealthDay News) -- A combination drug regimen that includes a derivative of thalidomide extended survival, as well as the time it took for the disease to reappear, in patients with multiple...

Studies attribute recent increase in multiple myeloma survival to novel therapies

(WASHINGTON, November 1, 2007) Multiple myeloma is one of the most common and devastating bone marrow cancers in the U.S., but survival rates have risen dramatically over the past decade. Recent analyses suggest that this trend may be attributed to new types of drugs and aggressive therapeutic in...

Thalidomide Improves Outcomes for Older Myeloma Patients

Adding the drug to standard chemo boosted survival, study found FRIDAY, Oct. 5 (HealthDay News) -- Elderly patients with multiple myeloma live longer when thalidomide is added to standard combination chemotherapy treatment, a new study finds. The finding could be the first real treatment adv...

Gene Test Could Boost Myeloma Treatment

Certain DNA influences who'll respond best to therapy, scientists say THURSDAY, Sept. 20 (HealthDay News) -- Analyzing the activity of a small subset of genes may help identify patients with the worst cases of multiple myeloma, U.S. researchers say. It may also help guide their treatment, not...

Gene profiling can single out the worst cases of multiple myeloma and guide therapy

ATLANTA Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potenti...

Human C-reactive protein regulates myeloma tumor cell growth and survival

Scientists report that a protein best known as a common marker of inflammation plays a key role in the progression of human cancer. The research, published by Cell Press in the September issue of the journal Cancer Cell, implicates C-reactive protein (CRP) as a potential target for cancer treatmen...

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathw...

Combination Therapy Helps to Combat Myeloma

Adding Velcade to standard drug therapy prolonged survival, study finds WEDNESDAY, Aug. 27 (HealthDay News) -- Patients with multiple myeloma who could not tolerate high dose chemotherapy lived longer and better by adding the drug Velcade to standard treatment, a new study found. Th...

Thalidomide Continues to Show Benefits Against Myeloma

The once-notorious drug aiding certain patients with the blood cancer WEDNESDAY, July 9 (HealthDay News) -- Researchers exploring the benefits of the once-banned drug thalidomide for patients with myeloma have learned a lesson that's as true to life as it is to science: Don't judge res...

One Gene May Be Key to Myeloma

The discovery holds promise as a treatment target for this diverse disease, experts say MONDAY, June 23 (HealthDay News) -- Cancerous myeloma cells are so "addicted" to a gene known as IRF4, they simply can't live without it, new research has revealed. Reducing the activity of the g...

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma

- New indication offers earlier treatment options for patients - CAMBRIDGE, Mass. and OSAKA, Japan, June 20 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced that the U.S. Food and Drug A...

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

Kosan Leads Industry with Most Advanced Hsp90 Inhibitor in Clinical Development New Supportive Trial in Less Refractory Patients to Replace Current TIME-2 Trial Conference Call and Webcast Today HAYWARD, Calif., ...

Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma

CAMBRIDGE, Mass., Dec. 21 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced the submission of a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) for VELCADE in the treatment of patients with previously untreated...

3-drug combination 'extremely promising' as first-line therapy for multiple myeloma

ATLANTAA new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology. The thre...

Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma

- VELCADE, thalidomide and dexamethasone improved pre - and post-stem cell transplantation results compared to thalidomide and dexamethasone - ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) reported the presenta...

Penn's Abramson Cancer Center part of major phase III study for myeloma

PHILADELPHIA Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow. The...

FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma

- Underscores Benefit for Patients with Kidney Impairments - - Highlights Leading Role of VELCADE in Broad Range of Patients - CAMBRIDGE, Mass., Oct. 15 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced that the U.S. Food and Drug Administratio...

The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma

Free, Interactive Telephone Education Program Features Myeloma Experts, Melissa Alsina, M.D. and Kathy A. Daily, R.N. WHITE PLAINS, N.Y., Oct. 4 /PRNewswire/ -- Myeloma patients can learn about managing side effects during a free telephone education workshop sponsored by The Leukem...

Emory researchers identify signaling protein for multiple myeloma

Researchers at Emory Universitys Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival. Their research may result in identification of a new therapeutic target for treating multiple myeloma. The results of the ...
Other Tags
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
(Date:3/18/2015)... As mobile payments become more prevalent ... and apps continue to be introduced into the market place ... payment industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... BABA ), Apple Inc. (NASDAQ: AAPL ), Google ... FB ) NXT-ID, Inc. (NASDAQ: ...
(Date:3/17/2015)... , March 17, 2015 Emotient, the ... software, today announced general availability of Emotient ... for the analysis of facial expressions. The system ... media content, products and services. It delivers audience ... and sentiment - as derived from facial evidence ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
(Date:3/26/2015)... On March 5, 2015, Portland Trail ... for the season with a torn Achilles tendon in ... Blazers were competing against Dallas, and was confirmed via ... Silva, M.D., who has treated many professional athletes, voiced ... could be prevented. , "Part of the problem ...
(Date:3/26/2015)... Spring, Md. (PRWEB) March 26, 2015 ... fully supports the Patients’ Access to Treatments Act ... Representatives this week by Reps. David B. McKinley ... legislation will limit cost-sharing requirements for medications placed ... more accessible by reducing patients’ out-of-pocket expenses. , ...
(Date:3/26/2015)... 26, 2015 Volunteers will collectively walk ... Parkinson’s disease and funds to support the American ... Burden – Find the Cure. The Optimism ... place in more than 20 locations including, Boston, Chicago, ... San Antonio, Minnesota, Seattle, St. Louis, New York, Nevada, ...
(Date:3/26/2015)... March 26, 2015 In preparation for ... Fitness Revolution, founded by Samir Becic, has issued ... own personal health and fitness, as well as their ... The list includes Sen. Ted Cruz, who has officially ... as all other politicians who have shown interest in ...
(Date:3/26/2015)... CRN International took the podium this week at ... achievement of jobseekers from five statewide locations as part ... , The program, called Platform to Employment and being ... the Connecticut Department of Labor, takes active steps to ... them at appropriate companies. CRN, a 40-year-old radio marketing ...
Breaking Medicine News(10 mins):Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4Health News:Pulmonary Hypertension Association Part of Coalition Supporting the Patients’ Access to Treatments Act 2Health News:American Parkinson Disease Association 2015 Optimism Walk Season Launches Nationwide 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:CRN International Shows Support For Groundbreaking Connecticut Program To Aid The Unemployed 2
Other Contents